Cargando…

Emerging Therapies in Chronic Spontaneous Urticaria

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Taek Ki, Saini, Sarbjit S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557779/
https://www.ncbi.nlm.nih.gov/pubmed/31172716
http://dx.doi.org/10.4168/aair.2019.11.4.470
_version_ 1783425491282165760
author Min, Taek Ki
Saini, Sarbjit S.
author_facet Min, Taek Ki
Saini, Sarbjit S.
author_sort Min, Taek Ki
collection PubMed
description Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.
format Online
Article
Text
id pubmed-6557779
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
record_format MEDLINE/PubMed
spelling pubmed-65577792019-07-01 Emerging Therapies in Chronic Spontaneous Urticaria Min, Taek Ki Saini, Sarbjit S. Allergy Asthma Immunol Res Review Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2019-05-22 /pmc/articles/PMC6557779/ /pubmed/31172716 http://dx.doi.org/10.4168/aair.2019.11.4.470 Text en Copyright © 2019 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Min, Taek Ki
Saini, Sarbjit S.
Emerging Therapies in Chronic Spontaneous Urticaria
title Emerging Therapies in Chronic Spontaneous Urticaria
title_full Emerging Therapies in Chronic Spontaneous Urticaria
title_fullStr Emerging Therapies in Chronic Spontaneous Urticaria
title_full_unstemmed Emerging Therapies in Chronic Spontaneous Urticaria
title_short Emerging Therapies in Chronic Spontaneous Urticaria
title_sort emerging therapies in chronic spontaneous urticaria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557779/
https://www.ncbi.nlm.nih.gov/pubmed/31172716
http://dx.doi.org/10.4168/aair.2019.11.4.470
work_keys_str_mv AT mintaekki emergingtherapiesinchronicspontaneousurticaria
AT sainisarbjits emergingtherapiesinchronicspontaneousurticaria